Drug Profile
ES 1
Alternative Names: ES1Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Essentys AB
- Class Osteoporosis therapies
- Mechanism of Action Collagen stimulants; Osteogenesis stimulants; Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Osteoporosis
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 25 May 2006 This compound is still in active development
- 25 May 2006 ES 1 is available for licensing (http://www.essentys.com)
- 30 Sep 2003 Phase-II clinical trials in Postmenopausal osteoporosis in Sweden (PO)